HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software

Stock Information for Heartbeam Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Heartbeam Inc.

HeartBeam Reports First Quarter 2025 Results
HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio
HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time
HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation
HeartBeam Reports Fourth Quarter and Full Year 2024 Results
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.